BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Reig M, Forner A, Rimola J, Ferrer-Fábrega J, Burrel M, Garcia-Criado A, Kelley RK, Galle PR, Mazzaferro V, Salem R, Sangro B, Singal AG, Vogel A, Fuster J, Ayuso C, Bruix J. BCLC strategy for prognosis prediction and treatment recommendation Barcelona Clinic Liver Cancer (BCLC) staging system. The 2022 update. J Hepatol 2021:S0168-8278(21)02223-6. [PMID: 34801630 DOI: 10.1016/j.jhep.2021.11.018] [Cited by in Crossref: 82] [Cited by in F6Publishing: 62] [Article Influence: 82.0] [Reference Citation Analysis]
Number Citing Articles
1 Elhence A, Shalimar. Liver dysfunction in Barcelona Clinic Liver Cancer-2022 update: clear as day or still in fog? J Hepatol 2021:S0168-8278(21)02291-1. [PMID: 34954248 DOI: 10.1016/j.jhep.2021.12.016] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Li XY, Shen Y, Zhang L, Guo X, Wu J. Understanding initiation and progression of hepatocellular carcinoma through single cell sequencing. Biochim Biophys Acta Rev Cancer 2022;:188720. [PMID: 35304295 DOI: 10.1016/j.bbcan.2022.188720] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Zanus G, Tagliente G, Rossi S, Bonis A, Zambon M, Scopelliti M, Brizzolari M, Grossi U, Romano M, Finotti M. Pulsed Microwave Liver Ablation: An Additional Tool to Treat Hepatocellular Carcinoma. Cancers (Basel) 2022;14:748. [PMID: 35159014 DOI: 10.3390/cancers14030748] [Reference Citation Analysis]
4 Mauro E, Forner A. Barcelona Clinic Liver Cancer 2022 update: Linking prognosis prediction and evidence-based treatment recommendation with multidisciplinary clinical decision-making. Liver Int 2022;42:488-91. [PMID: 35194931 DOI: 10.1111/liv.15180] [Reference Citation Analysis]
5 Ke Q, Xin F, Fang H, Zeng Y, Wang L, Liu J. The Significance of Transarterial Chemo(Embolization) Combined With Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma in the Era of Systemic Therapy: A Systematic Review. Front Immunol 2022;13:913464. [DOI: 10.3389/fimmu.2022.913464] [Reference Citation Analysis]
6 Falette Puisieux M, Pellat A, Assaf A, Ginestet C, Brezault C, Dhooge M, Soyer P, Coriat R. Therapeutic Management of Advanced Hepatocellular Carcinoma: An Updated Review. Cancers (Basel) 2022;14:2357. [PMID: 35625962 DOI: 10.3390/cancers14102357] [Reference Citation Analysis]
7 Hatzidakis A, Müller L, Krokidis M, Kloeckner R. Local and Regional Therapies for Hepatocellular Carcinoma and Future Combinations. Cancers (Basel) 2022;14:2469. [PMID: 35626073 DOI: 10.3390/cancers14102469] [Reference Citation Analysis]
8 Mansur A, Garg T, Shrigiriwar A, Etezadi V, Georgiades C, Habibollahi P, Huber TC, Camacho JC, Nour SG, Sag AA, Prologo JD, Nezami N. Image-Guided Percutaneous Ablation for Primary and Metastatic Tumors. Diagnostics 2022;12:1300. [DOI: 10.3390/diagnostics12061300] [Reference Citation Analysis]
9 Akce M, El-rayes BF, Bekaii-saab TS. Frontline therapy for advanced hepatocellular carcinoma: an update. Therap Adv Gastroenterol 2022;15:175628482210861. [DOI: 10.1177/17562848221086126] [Reference Citation Analysis]
10 Peng Y, He P, Gao X, Liu G, Cheng H. A Superstable Homogeneous Lipiodol-Nanoformulation to Overcome the Dilemma of Interventional Embolization Chemotherapy. Front Bioeng Biotechnol 2022;10:952194. [DOI: 10.3389/fbioe.2022.952194] [Reference Citation Analysis]
11 Mercan-stanciu A, Isac T, Rababoc R, Rusie D, Toma L, Vacaroiu IA, Tulin R, Iliescu EL. Multimodal Treatment of Hepatocellular Carcinoma in Patients With Hepatitis C Virus Infection Treated With Direct-Acting Antivirals. Cureus. [DOI: 10.7759/cureus.25487] [Reference Citation Analysis]
12 Cammarota A, Zanuso V, D'Alessio A, Pressiani T, Bozzarelli S, Personeni N, Rimassa L. The dual checkpoint blockade in unresectable hepatocellular carcinoma: Opportunities emerging in clinical trials. Expert Opin Investig Drugs 2022. [PMID: 35152830 DOI: 10.1080/13543784.2022.2042253] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Zhang Y, Zhang X, Kuang M, Yu J. Emerging insights on immunotherapy in liver cancer. Antioxid Redox Signal 2022. [PMID: 35754339 DOI: 10.1089/ars.2022.0047] [Reference Citation Analysis]
14 Cucarull B, Tutusaus A, Rider P, Hernáez-Alsina T, Cuño C, García de Frutos P, Colell A, Marí M, Morales A. Hepatocellular Carcinoma: Molecular Pathogenesis and Therapeutic Advances. Cancers (Basel) 2022;14:621. [PMID: 35158892 DOI: 10.3390/cancers14030621] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
15 Fulgenzi CAM, D'Alessio A, Ogunbiyi O, Demirtas CO, Gennari A, Cortellini A, Sharma R, Pinato DJ. Novel immunotherapy combinations in clinical trials for hepatocellular carcinoma: will they shape the future treatment landscape? Expert Opin Investig Drugs 2022;:1-11. [PMID: 35507361 DOI: 10.1080/13543784.2022.2072726] [Reference Citation Analysis]
16 Lewis S, Dawson L, Barry A, Stanescu T, Mohamad I, Hosni A. Stereotactic body radiation therapy for hepatocellular carcinoma: from infancy to ongoing maturity. JHEP Reports 2022. [DOI: 10.1016/j.jhepr.2022.100498] [Reference Citation Analysis]
17 Hendriks P, Rietbergen DDD, van Erkel AR, Coenraad MJ, Arntz MJ, Bennink RJ, Braat AE, Crobach ASLP, van Delden OM, van der Hulle T, Klümpen HJ, van der Meer RW, Nijsen JFW, van Rijswijk CSP, Roosen J, Ruijter BN, Smit F, Stam MK, Takkenberg RB, Tushuizen ME, van Velden FHP, de Geus-Oei LF, Burgmans MC; Dutch Hepatocellular Cholangiocarcinoma Group. Study Protocol: Adjuvant Holmium-166 Radioembolization After Radiofrequency Ablation in Early-Stage Hepatocellular Carcinoma Patients-A Dose-Finding Study (HORA EST HCC Trial). Cardiovasc Intervent Radiol 2022. [PMID: 35618860 DOI: 10.1007/s00270-022-03162-7] [Reference Citation Analysis]
18 Chapiro J. Translating artificial intelligence from code to bedside: The road towards AI-driven predictive biomarkers for immunotherapy of hepatocellular carcinoma. Journal of Hepatology 2022. [DOI: 10.1016/j.jhep.2022.03.035] [Reference Citation Analysis]
19 Jiang ST, Zhang JW, Lu X, Xu YY. Letter to the editor: Cautious use of multistate modeling in prognosis analysis of HCC. Hepatology 2022. [PMID: 35434818 DOI: 10.1002/hep.32533] [Reference Citation Analysis]
20 Lin P, Teng W, Jeng W, Chen W, Hsieh Y, Huang C, Lui K, Hung C, Wang C, Chai P, Lin C, Lin C, Lin S, Sheen I. Dynamic Change of Albumin-Bilirubin Score Is Good Predictive Parameter for Prognosis in Chronic Hepatitis C-hepatocellular Carcinoma Patients Receiving Transarterial Chemoembolization. Diagnostics 2022;12:665. [DOI: 10.3390/diagnostics12030665] [Reference Citation Analysis]
21 Kotsifa E, Vergadis C, Vailas M, Machairas N, Kykalos S, Damaskos C, Garmpis N, Lianos GD, Schizas D. Transarterial Chemoembolization for Hepatocellular Carcinoma: Why, When, How? JPM 2022;12:436. [DOI: 10.3390/jpm12030436] [Reference Citation Analysis]
22 Lachiondo-ortega S, Delgado TC, Baños-jaime B, Velázquez-cruz A, Díaz-moreno I, Martínez-chantar ML. Hu Antigen R (HuR) Protein Structure, Function and Regulation in Hepatobiliary Tumors. Cancers 2022;14:2666. [DOI: 10.3390/cancers14112666] [Reference Citation Analysis]
23 Ramtohul T, Vilgrain V, Soubrane O, Bouattour M, Luciani A, Kobeiter H, Mule S, Tacher V, Laurent A, Amaddeo G, Regnault H, Bulsei J, Nault J, Nahon P, Durand-zaleski I, Seror O. Impact of Extended Use of Ablation Techniques in Cirrhotic Patients with Hepatocellular Carcinoma: A Cost-Effectiveness Analysis. Cancers 2022;14:2634. [DOI: 10.3390/cancers14112634] [Reference Citation Analysis]
24 Su Y, Liu Y, Hsiao C, Hsu C, Chen L. Trial Designs for Integrating Novel Therapeutics into the Management of Intermediate-Stage Hepatocellular Carcinoma. JHC 2022;Volume 9:517-36. [DOI: 10.2147/jhc.s220978] [Reference Citation Analysis]
25 Ouyang T, Kan X, Zheng C. Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma: Monotherapies and Combined Therapies. Front Oncol 2022;12:898964. [DOI: 10.3389/fonc.2022.898964] [Reference Citation Analysis]
26 Choi SI, Cho Y, Ki M, Kim BH, Lee IJ, Kim TH, Kim SH, Koh YH, Kim HB, Hong EK, Kim CM, Park JW. Better survival of patients with hepatitis B virus-related hepatocellular carcinoma in South Korea: Changes in 16-years cohorts. PLoS One 2022;17:e0265668. [PMID: 35324973 DOI: 10.1371/journal.pone.0265668] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Borde T, Nezami N, Gaupp FL, Savic LJ, Taddei T, Jaffe A, Strazzabosco M, Lin M, Duran R, Georgiades C, Hong K, Chapiro J. Optimization of the BCLC Staging System for Locoregional Therapy for Hepatocellular Carcinoma by Using Quantitative Tumor Burden Imaging Biomarkers at MRI. Radiology 2022;:212426. [PMID: 35412368 DOI: 10.1148/radiol.212426] [Reference Citation Analysis]
28 Wang Q, Tan Y, Jiang T, Wang X, Li Q, Li Y, Dong L, Liu X, Xu G. Metabolic Reprogramming and Its Relationship to Survival in Hepatocellular Carcinoma. Cells 2022;11:1066. [PMID: 35406630 DOI: 10.3390/cells11071066] [Reference Citation Analysis]
29 d’Abadie P, Walrand S, Lhommel R, Hesse M, Borbath I, Jamar F. Optimization of the Clinical Effectiveness of Radioembolization in Hepatocellular Carcinoma with Dosimetry and Patient-Selection Criteria. Current Oncology 2022;29:2422-34. [DOI: 10.3390/curroncol29040196] [Reference Citation Analysis]
30 Hamaguchi K, Miyanishi K, Osuga T, Tanaka S, Ito R, Sakamoto H, Kubo T, Ohnuma H, Murase K, Takada K, Nagayama M, Kimura Y, Mizuguchi T, Takemasa I, Kato J. Association between Hepatic Oxidative Stress Related Factors and Activation of Wnt/β-Catenin Signaling in NAFLD-Induced Hepatocellular Carcinoma. Cancers 2022;14:2066. [DOI: 10.3390/cancers14092066] [Reference Citation Analysis]
31 Premkumar M, Anand AC. Overview of Complications in Cirrhosis. Journal of Clinical and Experimental Hepatology 2022. [DOI: 10.1016/j.jceh.2022.04.021] [Reference Citation Analysis]
32 Zheng J, Long H, Huang Y, Yan L, Yang J, Jiang L, Wu H. ASO Author Reflections: How to Choose the Optimal Strategy to Treat Patients with Moderately Advanced Multifocal Hepatocellular Carcinomas? Ann Surg Oncol. [DOI: 10.1245/s10434-022-11768-x] [Reference Citation Analysis]
33 Apisarnthanarax S, Cardenes H. In Reply to Nguyen et al. Pract Radiat Oncol 2022;12:e240. [PMID: 35512992 DOI: 10.1016/j.prro.2022.01.010] [Reference Citation Analysis]
34 Semmler G, Mandorfer M. Substantiating evidence for HCC risk stratification after cure of hepatitis C in patients with compensated advanced chronic liver disease. Journal of Hepatology 2022. [DOI: 10.1016/j.jhep.2022.04.031] [Reference Citation Analysis]
35 Leyh C, Ehmer U, Roessler D, Philipp AB, Reiter FP, Jeliazkova P, Jochheim LS, Jeschke M, Hammig J, Ludwig JM, Theysohn JM, Geier A, Lange CM. Sorafenib Versus Lenvatinib-Based Sequential Systemic Therapy for Advanced Hepatocellular Carcinoma: A Real-World Analysis. Cancers (Basel) 2022;14:1975. [PMID: 35454881 DOI: 10.3390/cancers14081975] [Reference Citation Analysis]
36 Kim E, Sher A, Abboud G, Schwartz M, Facciuto M, Tabrizian P, Knešaurek K, Fischman A, Patel R, Nowakowski S, Llovet J, Taouli B, Lookstein R. Radiation segmentectomy for curative intent of unresectable very early to early stage hepatocellular carcinoma (RASER): a single-centre, single-arm study. The Lancet Gastroenterology & Hepatology 2022. [DOI: 10.1016/s2468-1253(22)00091-7] [Reference Citation Analysis]
37 Lv YF, Deng ZQ, Bi QC, Tang JJ, Chen H, Xie CS, Liang QR, Xu YH, Luo RG, Tang Q. Intratumoral Pi deprivation benefits chemoembolization therapy via increased accumulation of intracellular doxorubicin. Drug Deliv 2022;29:1743-53. [PMID: 35635315 DOI: 10.1080/10717544.2022.2081384] [Reference Citation Analysis]
38 Wang K, Sun L, Wang M. Methodological considerations regarding a gene signature to predict microvascular invasion in hepatocellular carcinoma. Journal of Hepatology 2022. [DOI: 10.1016/j.jhep.2022.04.027] [Reference Citation Analysis]
39 Zhang S, Zhong BY, Zhang L, Wang WS, Ni CF. Transarterial chemoembolization failure/refractoriness: A scientific concept or pseudo-proposition. World J Gastrointest Surg 2022; 14(6): 528-537 [DOI: 10.4240/wjgs.v14.i6.528] [Reference Citation Analysis]
40 Solbiati M, Ierace T, Muglia R, Pedicini V, Iezzi R, Passera KM, Rotilio AC, Goldberg SN, Solbiati LA. Thermal Ablation of Liver Tumors Guided by Augmented Reality: An Initial Clinical Experience. Cancers 2022;14:1312. [DOI: 10.3390/cancers14051312] [Reference Citation Analysis]
41 Galun D, Mijac D, Filipovic A, Bogdanovic A, Zivanovic M, Masulovic D. Precision Medicine for Hepatocellular Carcinoma: Clinical Perspective. JPM 2022;12:149. [DOI: 10.3390/jpm12020149] [Reference Citation Analysis]
42 Sangro B, Argemí J. Immunotherapy in HCC-No rush despite the hype. Hepatology 2022. [PMID: 35491442 DOI: 10.1002/hep.32550] [Reference Citation Analysis]
43 Deng J, Wen F. Transarterial Chemoembolization Combined With Tyrosine Kinase Inhibitors for Intermediate-Stage Hepatocellular Carcinoma, What Else Can We Do? Front Oncol 2022;12:824799. [PMID: 35425716 DOI: 10.3389/fonc.2022.824799] [Reference Citation Analysis]
44 Matilla AM, Varela M, Reig M. The complex management of hepatocellular carcinoma: a major need of expertise. Rev Esp Enferm Dig 2022. [PMID: 35656920 DOI: 10.17235/reed.2022.8953/2022] [Reference Citation Analysis]
45 Xu X, Lau WY, Yang T. The Updated BCLC Staging System Needs Further Refinement: A Surgeon’s Perspective. Journal of Hepatology 2022. [DOI: 10.1016/j.jhep.2022.01.002] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
46 Tella SH, Kommalapati A, Mahipal A, Jin Z. First-Line Targeted Therapy for Hepatocellular Carcinoma: Role of Atezolizumab/Bevacizumab Combination. Biomedicines 2022;10:1304. [DOI: 10.3390/biomedicines10061304] [Reference Citation Analysis]
47 Melendez-Torres J, Singal AG. Early detection of hepatocellular carcinoma: roadmap for improvement. Expert Rev Anticancer Ther 2022. [PMID: 35514249 DOI: 10.1080/14737140.2022.2074404] [Reference Citation Analysis]
48 Zingoni A, Banales JM. PIGR-enriched circulating vesicles contributes to hepatocellular carcinoma aggressiveness. J Hepatol 2022:S0168-8278(22)00070-8. [PMID: 35149124 DOI: 10.1016/j.jhep.2022.02.001] [Reference Citation Analysis]
49 Montazeri SA, De la Garza-Ramos C, Lewis AR, Lewis JT, LeGout JD, Sella DM, Paz-Fumagalli R, Devcic Z, Ritchie CA, Frey GT, Vidal L, Croome KP, McKinney JM, Harnois D, Krishnan S, Patel T, Toskich BB. Hepatocellular carcinoma radiation segmentectomy treatment intensification prior to liver transplantation increases rates of complete pathologic necrosis: an explant analysis of 75 tumors. Eur J Nucl Med Mol Imaging 2022. [PMID: 35441860 DOI: 10.1007/s00259-022-05776-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
50 Ju S, Zhou C, Hu J, Wang Y, Wang C, Liu J, Yang C, Huang S, Li T, Chen Y, Bai Y, Yao W, Xiong B. Late combination of transarterial chemoembolization with apatinib and camrelizumab for unresectable hepatocellular carcinoma is superior to early combination. BMC Cancer 2022;22. [DOI: 10.1186/s12885-022-09451-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
51 Maestri M, Pallozzi M, Santopaolo F, Cerrito L, Pompili M, Gasbarrini A, Ponziani FR. Durvalumab: an investigational agent for unresectable hepatocellular carcinoma. Expert Opinion on Investigational Drugs. [DOI: 10.1080/13543784.2022.2033208] [Reference Citation Analysis]
52 Tibballs J, Clements W. Immunotherapy and Transarterial therapy of HCC: What the interventional radiologist needs to know about the changing landscape of HCC treatment? J Med Imaging Radiat Oncol 2022. [PMID: 35357076 DOI: 10.1111/1754-9485.13405] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
53 Sekiguchi S, Tsuchiya K, Yasui Y, Inada K, Kirino S, Yamashita K, Hayakawa Y, Osawa L, Higuchi M, Takaura K, Maeyashiki C, Kaneko S, Tamaki N, Nakanishi H, Itakura J, Takahashi Y, Asahina Y, Okamoto R, Kurosaki M, Izumi N. Clinical usefulness of geriatric assessment in elderly patients with unresectable hepatocellular carcinoma receiving sorafenib or lenvatinib therapy. Cancer Rep (Hoboken) 2022;:e1613. [PMID: 35302279 DOI: 10.1002/cnr2.1613] [Reference Citation Analysis]
54 Piscaglia F. Microwave ablation in skilled hands. A treatment opportunity gaining room in the field of single HCC 3-5 cm. Hepatology 2022. [PMID: 35092021 DOI: 10.1002/hep.32370] [Reference Citation Analysis]
55 Hucke F, Pinter M, Hucke M, Bota S, Bolf D, Hackl M, Peck-radosavljevic M. Changing Epidemiological Trends of Hepatobiliary Carcinomas in Austria 2010–2018. Cancers 2022;14:3093. [DOI: 10.3390/cancers14133093] [Reference Citation Analysis]
56 Katariya NN, Lizaola-Mayo BC, Chascsa DM, Giorgakis E, Aqel BA, Moss AA, Uson Junior PLS, Borad MJ, Mathur AK. Immune Checkpoint Inhibitors as Therapy to Down-Stage Hepatocellular Carcinoma Prior to Liver Transplantation. Cancers (Basel) 2022;14:2056. [PMID: 35565184 DOI: 10.3390/cancers14092056] [Reference Citation Analysis]
57 Papaconstantinou D, Hewitt DB, Brown ZJ, Schizas D, Tsilimigras DI, Pawlik TM. Patient stratification in hepatocellular carcinoma: impact on choice of therapy. Expert Rev Anticancer Ther 2022. [PMID: 35157530 DOI: 10.1080/14737140.2022.2041415] [Reference Citation Analysis]
58 Choo SP, Nahon P. Atezolizumab and bevacizumab for HCC in the real world. Liver Int 2022;42:727-8. [PMID: 35289074 DOI: 10.1111/liv.15204] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
59 Shirono T, Iwamoto H, Niizeki T, Shimose S, Kajiwara A, Suzuki H, Kamachi N, Noda Y, Okamura S, Nakano M, Kuromatsu R, Murotani K, Koga H, Torimura T. Durable complete response is achieved by balloon-occluded transcatheter arterial chemoembolization for hepatocellular carcinoma. Hepatol Commun 2022. [PMID: 35656864 DOI: 10.1002/hep4.2016] [Reference Citation Analysis]
60 Ivanics T, Claasen MP, Patel MS, Hansen BE, Sapisochin G. Reply. Hepatology 2022. [PMID: 35435274 DOI: 10.1002/hep.32532] [Reference Citation Analysis]
61 Tan L, Xu Z, Mao Q, Zhou S, Zhu J, Zhang X, Li H. Purified PTEN-Long Induces Liver Cancer Cells to Undergo Autophagy and Apoptosis. Front Surg 2022;9:767611. [DOI: 10.3389/fsurg.2022.767611] [Reference Citation Analysis]
62 Danso KA, Akuaku RS, Taylor RR, Amoako E, Ulzen‐appiah K, Jimah BB, Tagoe LG. A case report of a teenager with hepatitis B surface antigen‐positive multifocal hepatocellular carcinoma in a noncirrhotic liver. Clinical Case Reports 2022;10. [DOI: 10.1002/ccr3.5622] [Reference Citation Analysis]
63 Zane KE, Nagib PB, Jalil S, Mumtaz K, Makary MS. Emerging curative-intent minimally-invasive therapies for hepatocellular carcinoma. World J Hepatol 2022; 14(5): 885-895 [DOI: 10.4254/wjh.v14.i5.885] [Reference Citation Analysis]